Investors & Media
Company Overview
View All
LyGenesis’s cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. Our pipeline of therapies target a variety of unmet needs, including end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorder.
Featured News
The Prototype: This Startup Aims To Grow New Mini-Organs In Patients
Every year, over 50,000 patients die from liver disease in the United States. For many of these patients, a liver transplant is their only hope for treatment. But there often aren’t enough donor livers to go around, plus many patients aren’t eligible for liver transplant, often due to factors beyond their control.
Michael Hufford wants to change that. He’s the CEO of Pittsburgh-based Lygenesis, which has developed the technology to induce a patient’s own lymph nodes to grow miniature livers, which can carry out many of the liver’s functions and help patients stay healthy.
Read More 
